Effects of prostaglandin E1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure

Japanese Heart Journal

Volumn 40, Issue 3, 1999, Pages 321-334

  Wimmer, Andreas ^b   Stanek, Brigitte ^a   Kubecova, Lea ^b   Vitovec, Jiri ^b   Spinar, Jindrich ^b   Yilmaz, Nilgryn ^b   Kos, Thomas ^b   Hartter, Engelbert ^b   Frey, Bernhard ^b   Pacher, Richard ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Advanced heart failure; Dobutamine; Glomerular filtration rate; Hemodynamics; Prostaglandin E1; Renal plasma flow

Indexed keywords

4 AMINOHIPPURIC ACID; ATRIAL NATRIURETIC FACTOR; CARDIOTONIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENALAPRIL; ENDOTHELIN; IOTALAMIC ACID; NORADRENALIN; PROSTAGLANDIN E1;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HEART FAILURE; HEART INDEX; HEART OUTPUT; HEART PALPITATION; HEART RIGHT ATRIUM PRESSURE; HEMODYNAMICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY PLASMA FLOW; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; MYALGIA; NORADRENALIN BLOOD LEVEL; ORAL DRUG ADMINISTRATION; PARALLEL DESIGN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE;

ALPROSTADIL; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIOTONIC AGENTS; DOBUTAMINE; ENDOTHELINS; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE, CONGESTIVE; HEART RATE; HEMODYNAMIC PROCESSES; HUMANS; MALE; MIDDLE AGED; NOREPINEPHRINE; PROSPECTIVE STUDIES; RENAL CIRCULATION; VASODILATOR AGENTS;

EID: 0033066252     PISSN: 00214868     EISSN: None     Source Type: Journal    
DOI: 10.1536/jhj.40.321     Document Type: Article

References (35)

1. Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO. Current medical therapy for advanced heart failure. Am Heart J 1998; S 231-48.
2. Miller LW, Merkle EJ, Jennison SH. Outpatient use of dobutamine to support patients awaiting heart transplantation. J Heart Lung Transplant 1994; 13: S 126-9.
3. Sindone AP, Keogh AM, McDonald PS, McCosker CJ, Kaan AF. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Am Heart J 1997: 134: 889-900.
4. Cesario D, Clark J, Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 1998; 135: 121-9.
5. Yui Y, Nakajima H, Kawai C, Murakami T. Prostacyclin therapy in patients with congestive heart failure. Am J Cardiol 1981; 50: 320-4.
6. Sueta CA, Gheorghiade M, Adams KF, et al. Safety and efficacy of epoprostenol in patients with severe congestive heart failure. Am J Cardiol 1995; 75: 34A-43A.
7. Pacher R, Stanek B, Hülsmann M, et al. Prostaglandin E1-bridge to cardiac transplantation: technique, dosage, results. Eur Heart J 1997; 18: 318-29.
8. Hülsmann M, Stanek B, Frey B, et al. Hemodynamic and neurohumoral effects of long-term PGE1 infusions in outpatients with severe congestive heart failure. J Heart Lung Transplant 1997; 16: 556-62.
9. Knaus WA, Harrell FE Jr, Lynn J, et al. The SUPPORT prognostic model. Objective estimates of survival for seriously ill hospitalized adults: study to understand prognoses and preferences for outcomes and risks of treatments. Ann Intern Med 1995; 122: 191-203.
10. Dies F. Intermittent dobutamine in ambulatory patients with chronic cardiac failure. Br J Clin Pract 1986; 45 (suppl) 37-40.
11. Califf RM, Adams KF, McKenna, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST) . Am Heart J 1997; 134: 44-54.
12. Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation 1978; 58; 466-75.
13. Kubo S, Stevenson L, Miller L, et al. Outcomes in non-urgent patients (status II) awaiting transplantation: risk factors for death or deterioration to status I (urgent status). J Heart Lung Transplant 1997; 16: 44.
14. Horrobin DF. The investigation of prostaglandin action. In: Horrobin DF, editor. Prostaglandins, Physiology, Pharmacology and Clinical Significance. Montreal: Eden Press 1978: 59-76.
15. Adachi H, Sugihara H, Nakagawa H, Ochiai M, Nagakawa M, Ijichi H. Effect of PGE1 on fractional distribution of cardiac output and organ blood flow in man: a simultaneous and noninvasive determination using double dose thallium-201 scintigraphy. Cardiovasc Res 1984; 18: 675-62.
16. Pacher R, Stanek B, Hülsmann B, Sinzinger H. Effect of prostaglandin E1 infusion in severe chronic heart failure. Prostaglandins 1997: 53: 221-35.
17. Pacher R, Stanek B, Hulsmann M, et al. Prostaglandin E1 infusion compared with prostacyclin infusion in patients with refractory heart failure: effects on hemodynamics and neurohumoral variables. J Heart Lung Transplant 1997; 16: 878-81.
18. Oberbauer R, Haas M, Regele H, Barnas U, Schmidt A, Mayer G. Glomerular permselectivity in proteinuric patients after kidney transplantation. J Clin Invest 1995; 96: 22-9.
19. Schuller M, Stetter R, Skrabal S, Missbichler A, Woloszczuk W, Hartter E. Radioimmunoassay of immunoreactive C-terminal big-endothelin. Eur J Clin Chem Clin Biochem 1991; 29: 147-50.
20. Eriksson BM, Persson BA. Determination of catecholamines in rat heart tissue and plasma samples by liquid chromatography with electrochemical detection. J Chromatogr 1982; 228: 143-54.
21. Stanek B, Pacher R. Dose-effect relationships of prostaglandin E1 in severe endstage chronic heart failure. Jpn Heart J 1997; 38: 53-65.
22. Rickenbacher PR, Trindade PT, Haywood GA, et al. Transplant candidates with severe left ventricular dysfunction managed with medical treatment: characteristics and survival. J Am Coll Cardiol 1996; 27: 1182-7.
23. Paul O, Vawter GF, Schweitzer AW, Hass GW. Pathological changes in congestive heart failure. AMA Arch Pathol 1957; 64: 363-80.
24. Pacher R, Stanek B, Hülsmann M, et al. Prognostic impact of plasma big endothelin 1 as compared to invasive hemodynamic evaluation in severe heart failure. J Am Coll Cardiol 1996 27: 633-41
25. Stanek B, Frey B, Hülsmann M, et al. Validation of big endothelin plasma levels compared to established neurohumoral markers in patients with severe chronic heart failure. Transpl Proc 1997; 29: 595-6.
26. Hülsmann M, Stanek B, Frey B, et al. Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure. J Am Coll Cardiol 1998; 32: 1695-700.
27. Lewis RM, Verani RR, Vo C, et al. Evaluation of chronic renal disease in heart transplant recipients: importance of pretransplantation native histologic evaluation. J Heart Lung Transplant 1994; 13: 376-80.
28. Carmines PK, Perr MD, Hazelrig JB, Navar G. Effects of preglomerular and postglomerular vascular resistance alterations on filtration fraction. Kidney Int 1987; 31 (suppl 20): S 229-32.
29. Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure: relationship of cardiac index to kidney function. Drugs 1990; 39 (suppl 4): 10-21.
30. Menashe PI, Ross SA, Gottlieb JE. Acquired renal insufficiency in critically ill patients. Crit Care Med 1988; 16: 1106-9.
31. Nakano J, McCurdy JR. Cardiovascular effects of prostaglandin E. J Pharmacol Exp Ther 1967; 156: 538-47.
32. Johnston HH, Herzog JP, Lauler DP. Effect of prostaglandin E1 on renal hemodynamics, sodium and water excretion. Am J Physiol 1967; 213: 939-46.
33. Goto F, Otani E, Kato S, Fujita T. Prostaglandin E1 as a hypotensive drug during general anaesthesia. Anaesthesia 1982; 37: 530-5.
34. Riegger AJ. Role of prostaglandins in regulation of kidney function in heart failure. Herz 1991; 16: 116-23.
35. Yamada S, Hamatani K, Kishizuchi S, et al. Evaluation of the renal function during hypotensive anaesthesia induced by nitroglycerin, prostaglandin E1 or nitroglycerin + prostaglandin E1. Masui (Jpn J Anaesthesiol) 1993; 42: 1009-12 (in Japanese).